Background: The gamma-aminobutyric acid (GABA) hypothesis in essential tremor (ET) implies a disturbance of the GABAergic system, especially involving the
Introduction
Essential tremor (ET) is a common movement disorder in adults, characterized by rhythmic shaking of the arms and possibly other parts of the body. It is often referred to as a benign disorder but moderate and advanced stages of ET can be physically and socially disabling. 1 The few medications that have been used to treat ET have demonstrated only modest efficacy.
humans. Clinical case studies have shown that lesions of these structures can alleviate tremor. 4, 5 The ventral intermediate (VIM) nucleus is the most effective target for stereotactic interventions to treat tremor. 6 Two studies using repetitive transcranial magnetic stimulation applied over the cerebellum found a tremorlytic action in ET patients. 7, 8 Furthermore, positron emission tomography (PET) activation studies show regional cerebral blood flow in the cerebellum is abnormally increased. 9-11 Magnetic resonance imaging (MRI) studies including spectroscopy, voxel-based morphometry and functional MRI also support cerebellar involvement in ET. [12] [13] [14] Furthermore, microscopic cerebellar pathology has been identified in these patients, with cerebellar Purkinje cell loss with torpedoes and Bergmann gliosis. 15 In 2007, Louis and coworkers 15 studied 33 ET brains and found that about 75% of cases exhibited cerebellar pathology with a loss of Purkinje cells and increased numbers of axonal torpedoes. Further studies by the same group confirmed these findings. [16] [17] [18] Cerebellar Purkinje cells are large neurons that have many branching extensions. They are found in the cortex of the cerebellum and play a fundamental role in controlling motor movement. 19 These cells are characterized by cell bodies that are flash-like in shape, the result of numerous branching dendrites, and by a single long axon. Most Purkinje cells release the neurotransmitter GABA, which exerts inhibitory actions on the dentate nucleus and certain deep cerebellar output neurons, thereby reducing the transmission of nerve impulses. These inhibitory functions enable Purkinje cells to regulate and coordinate motor movements. GABA is the major neurotransmitter for fast inhibitory synaptic transmission. 19 Because of its widespread presence and utilization, this neurotransmitter is involved in all functions of the central nervous system, including the cerebellum. In fact, the GABA system is the target of a wide range of drugs that act on the central nervous system, such as anxiolytics, sedative-hypnotics, general anesthetics, and anticonvulsants.
GABA is synthesized by a specific enzyme, L-glutamic acid decarboxilase (GAD) in one step from L-glutamate. Thus, glutamate must be available in certain nerve endings for biosynthesis of GABA. Much of the glutamate and GABA used as a neurotransmitter is derived from glial storage pools of glutamine. GABA is released from electrically stimulated inhibitory nerve cells. The application of GABA and structural analogues to cells innervated by GABAergic neurons produces effects on that target cell identical to those produced by stimulating the inhibitory innervation.
GABA binds to and mediates its effects via post-synaptic ionotropic GABA A receptors and pre-and post-synaptic metabotropic GABA B receptors. 19, 20 Whereas the GABA A receptors mediate fast responses, the GABA B receptors mediate slow responses. GABA is removed from the synaptic cleft by GABA transporters and metabolized. The GABA A receptors are the main players in central nervous system (CNS) function and relevance to psychopharmacology. These are the sites of action of benzodiazepines, barbiturates, alcohol, general anesthetics, and neurosteroids.
Cerebrospinal fluid studies
In 1996, Mally et al. 21 compared the concentrations of amino acids in the cerebrospinal fluid (CSF) and serum in 20 patients with ET with those of a control group of 10 subjects. They found a slight increase in the concentration of glutamate and reduced levels of GABA, together with a decrease in glycine and serine and a slight increase in the concentration of glutamate. This work suggested a GABAergic dysfunction in ET and was one of the first to provide evidence favoring the GABA hypothesis. Indeed, the pathophysiological basis of ET seemed simple and would be the result of a decrease in GABA, the main brain inhibitory neurotransmitter. However, this is the only study analyzing GABA levels in CSF and the data have not been replicated.
Pathologic studies
A neuropathological study in 1996 20 revealed that GABA B receptors are present on the presynaptic terminals of Purkinje cells in the deep cerebellar nuclei. These anatomical structures have since been considered involved in the probable genesis of ET. A more recent neuropathological study on the GABA hypothesis in ET found interesting results that agree with this hypothesis. In 2012 Paris-Robidas et al. 22 reported a post-mortem decrease in GABA A (35% reduction) and GABA B (22-31% reduction) receptors in the dentate nucleus of the cerebellum in individuals with ET (n510) when compared to controls (n516) or individuals with Parkinson's disease (n510), as assessed by receptor-binding autoradiography. Furthermore, concentrations of GABA B receptors in the dentate nucleus were inversely correlated with the duration of ET symptoms, suggesting that the loss of GABA B receptors follows the progression of the disease. The authors proposed that a decrease in GABA receptors in the dentate nucleus disinhibits cerebellar pacemaker output activity, propagating along the cerebello-thalamo-cortical pathways to generate tremors.
In the same year, Shill et al. 23 studied some biochemical changes in autopsied patients with ET comparing them with a control group. They found significant reduced levels of parvalbumin (a marker of GABAergic Theophylline, 1991 39 Axelrad et al. 16 Paris-Robidas et al. 22 Pinault and Deschenes 28 Gironell et al. 36 Muscimol, 1991 40 Louis et al. 18 Shill et al. 23 Gabapentin 20 Even more compelling is the demonstration that deep cerebellar nuclei neurons can impose their rhythmicity to their thalamic target neurons with highly regular patterns of activity. 28 
Genetic studies
After several lines of evidence supported the GABA hypothesis, a number of works in the last 10 years have analyzed the genetic bases of this theory. The first approximation was negative. In 2006, Deng et al. 29 investigated the association between the GABA A receptor alpha-1 and ET in 76 familial ET patients. The association did not turn out to be significant. The authors concluded that missense, nonsense, or splice site mutations in the coding regions of the GABA A1 gene are not a major genetic cause of ET. More recent studies have been also negative. In 2011, Thier et al. 30 investigated an association between polymorphisms in 15 GABA A and four GABA transporter genes in ET. A total of 503 ET patients and 818 controls were analyzed. The authors did not find any evidence of an association between GABA A and GABA transporter genes in ET. García-Martin et al. 31 published two further negatives studies in 2011. In the first, they investigated the possible association between the GABA receptor subtypes rho1, rho2, and rho3 and allelic variants of the single nucleotide polymorphisms GABRR1-M26V, GABRR1-H27R, GABRR2-T455M, and GABRR3-Y205X and the risk of ET. The frequencies of GABBR1 genotypes and allelic variants of the studied polymorphisms did not differ significantly between patients with ET and controls and were unrelated to the age at onset of tremor, gender, localization of tremor, and response of tremor to ethanol. In a second work, the same authors studied the allelic and genotype frequencies for single nucleotide polymorphisms, such as GABRA4-L26M, GABRE-S102A, and GABRQ-I478F, in 200 patients with familial ET and 250 healthy controls using TaqMan genotyping.
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Genotype and allelic frequencies did not differ significantly between patients with ET and controls. The results of this study suggest that the single nucleotide polymorphisms studied in the GABRA4, GABRE, and GABRQ genes are not related to the risk for familial ET.
However, genetic studies in ET have several methodological shortcomings: a lack of stringent diagnostic criteria, small sample sizes, a lack of biomarkers, a high phenocopy rate, evidence of nonmendelian inheritance, and high locus heterogeneity in presumably monogenic ET. 33 
Experimental animal models
In 2005, Kralic et al. 34 performed an interesting investigation using GABA(A) receptor alpha-1 subunit knockout mice. This mouse model exhibited postural and kinetic tremor and motor incoordination characteristic of ET. The mice were tested using current ET drug therapies such as primidone, propranolol, and gabapentin, and the amplitude of the pathologic tremor decreased. Non-sedative doses of ethanol eliminated tremor. No differences in abundance, gross morphology, or spontaneous synaptic activity were observed in cerebellar Purkinje cells. These cells exhibited a profound loss of all responses to synaptic or exogenous GABA. The authors concluded that this genetic animal model elucidates a mechanism of GABAergic dysfunction in the major motor pathway and potential targets for pharmacotherapy of ET.
In vivo imaging studies The results from both studies showed complete agreement with the GABA hypothesis. Both studies provide neuroimaging evidence of abnormally increased GABA A receptor binding in ET, especially in cerebello-thalamic output pathways. In fact, the binding changes were located in regions implicated in tremor genesis, such as the thalamus, the cerebellum, and the lateral premotor cortex. We can conclude from these findings that in vivo neuroimaging studies support the role of cerebellar GABAergic dysfunction as the main pathophysiological hypothesis of the disease.
Human drug therapies
One of the major premises of the GABA hypothesis in ET was the antitremoric effects observed in some GABAergic drugs, such as gabapentin, in the late 1990s.
Progabide. The first controlled trial of a GABA-agonist, progabide, in ET was performed in 1983. Mondrup et al. 37 performed a study in 18 ET patients. They found no significant differences between progabide and placebo in tremor scores. Four years later, Koller et al. 38 performed another controlled trial with progabide in 10 ET patients. Again, there were no differences on tremor scores from placebo. The authors concluded that alterations in GABA neurotransmission do not appear to be involved in the pathogenesis of ET.
Theophylline. In 1991, Mally et al. 39 studied the effects of theophylline in 20 ET patients in a double-blind crossover trial. Tremor improved significantly after 4 weeks of treatment. The authors hypothesized that theophylline-enhanced GABA explains the antitremoric effect.
Muscimol. In 1999, Pahapill et al. 40 performed an interesting experiment injecting muscimol (GABA A agonist) into the ventralis intermedius thalamus in six patients undergoing stereotactic procedures for ET. The drug was administered in areas where tremor-synchronous cells were identified electrophysiologically with microelectrode recordings and where tremor reduction occurred with electrical microstimulation. Injections of muscimol but not saline solution consistently reduced tremor in each patient. The authors concluded that GABA-mediated thalamic neuronal inhibition may represent a mechanism underlying the effectiveness of surgery for tremor and that GABA analogues could potentially be used therapeutically.
Gabapentin. Gabapentin is structurally related to the neurotransmitter GABA. It penetrates the blood-brain barrier but it does not modify GABA A or GABA B radioligand binding, it is not converted metabolically into GABA or a GABA agonist, and it is not an inhibitor of GABA uptake or degradation. Its mechanism of action is not fully understood, but recent data indicate that it can increase human brain GABA levels and reduce intracortical excitability. In 1999, Gironell et al. 41 performed a randomized placebocontrolled comparative trial of gabapentin and propranolol in 16 ET patients. The patients were not taking antitremoric medication. On day 15, both gabapentin and propranolol demonstrated significant and comparable efficacy in reducing tremor from baseline in all tremor measures (clinic and accelerometric). Results of the study were in accordance with the central mechanism hypothesis that implicates the GABAergic system in the pathogenesis of ET. The authors concluded that their exploratory study suggested gabapentin deserved a role in the pharmacological treatment of ET.
In the same year, Pahwa et al. 42 performed another controlled study of gabapentin in ET in 20 ET patients. Although some patient had benefits on tremor, the results were not statistically significant for total tremor scores.
One year later, Ondo et al. 43 performed a multiple-dose, doubleblind, placebo-controlled trial with gabapentin in 25 ET patients. Some end points of the study were positive (patient global assessment, water-pouring scores, observed tremor scores, and activities of daily living). However, accelerometry, spirographs, and investigator global impressions scores did not improve. The results were similar for high and low doses. The authors concluded that gabapentin may be effective in some cases of ET.
In the American Academy of Neurology (AAN) recent guidelines for ET, gabapentin appeared with a type B level of evidence. 44 Topiramate. Topiramate is an anticonvulsant that blocks sodium channels and potentiates GABA activity. Following the GABA hypothesis in ET, several trials were done using this drug for ET. In 2002, Connor 45 found significant antitremoric properties of topiramate in a controlled study in 24 ET patients. Topiramate improved all tremor clinical scores. In a multicenter-controlled study, Ondo et al., 46 revealed significant improvement in tremor in 208 ET patients.
The mean percentage improvement in overall scores was 29%. In 2006, Frima and Grünewald, 47 performed a controlled crossover study of topiramate in 16 ET patients. The study was negative, and provided no evidence of therapeutic benefit of topiramate in ET. And in 2008, Connor et al. 48 performed a double-blind placebo controlled crossover study of topiramate in ET with 62 patients. The authors found a significant improvement (18-23%) in all tremor measures following treatment with topiramate. However, the drop-out rate was approximately 40% due to appetite suppression, weight loss, paresthesias, anorexia, and concentration difficulties. Tremor efficacy of topiramate is similar to gabapentin, but titration is long and difficult, and tolerance is poor. In recent AAN guides for ET treatment, topiramate is considered a second-line therapy with a level of evidence B. 44 Tiagabine. Tiagabine is a centrally acting GABA uptake inhibitor that allows more GABA to be available for post-synaptic receptor binding. Following the GABA hypothesis in ET, tiagabine may have antitremoric properties in ET patients.
Gironell et al. 49 performed an open-label trial with seven ET patients. Results were negative, and at the dosage tested they did not lead to a significant improvement in tremor amplitudes in ET.
Pregabaline. Pregabaline is a structural derivative of the inhibitory neurotransmitter GABA. In a similar way to gabapentin, it does not bind directly to GABA A , GABA B , or benzodiazepine receptors, does not increase GABA responses in cultured neurons, and does not alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, in cultured neurons, prolonged application of pregabaline increases the density of GABA transporter protein and increases the rate of functional GABA transport. published a study of pregabalin in 29 ET patients. The study was negative, and there were no improvements in any tremor measures.
Other drugs that enhance GABAergic transmission. Several classes of drugs that enhance GABAergic transmission by binding to sites on the GABA A receptors are effective in the treatment of ET. These include barbiturates (fenobarbital, primidone), and benzodiazepines (alprazolam and clonacepam). Primidone is a first-class antitremoric agent that has a similar efficacy to beta-blockers (level of evidence AAN: B). 53, 54 Alprazolam is probably efficacious in treating ET (level of evidence AAN: C). 55 Ethanol, which is often highly effective in reducing the severity of tremor in ET, potentiates the activity of the GABA A receptor. 56 Alcohol, in fact, is an indirect GABA agonist. It is believed to mimic GABA's effect on the brain, binding to GABA receptors and inhibiting neuronal signaling.
While propranolol is believed to have a therapeutic effect on ET by antagonistic binding to non-specific peripheral beta-adrenergic receptors, there is some evidence to suggest that it may also act by enhancing GABA receptivity in the central nervous system. 57 GABA hypothesis in ET: light N Step 1: cerebellar neurodegeneration with cerebellar Purkinje cell loss. Some pathological post-mortem studies agree with the GABA hypothesis, revealing Purkinje cell loss in ET. [15] [16] [17] [18] Furthermore, the neurodegenerative nature of ET is supported by the progressive course of the disease. -CSF studies demonstrating a decrease in GABA levels. 21 -Pathological studies that found a decrease in GABA receptors in the dentate nucleus.
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-In vivo imaging studies, with an increase of binding of flumazenil in GABA receptors in the cerebellar area, thus, suggesting a deficit in GABA in these areas. Fludeoxyglucose (FDG).
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-The antitremoric effect of inhibitory repetitive transcranial magnetic stimulation (rTMS) over the cerebellum also supports an increase in hypermetbolism and activity in this area. Thalamic rhythmic or tremoric neurons, specifically in VIM nucleus, have been clearly seen in electrophysiological recordings in deep brain stimulation surgery. 59, 60 GABA hypothesis in ET: lights and shadows
There are a number of arguments against the GABA hypothesis in ET. The main one is that evidence of a decrease in cerebellar GABA activity is based on relatively few studies. Only one study has found a decrease in GABA in CSF and only one neuropathological study has revealed a decrease in GABA receptors. Besides, only two controlled studies have analyzed in vivo imaging data.
There are several other important shadows hanging over the GABA hypothesis. The neuropathology of ET, in particular cerebellar pathology, is a matter of controversy. Several post-mortem studies have not revealed Purkinje cell loss in ET. [61] [62] [63] However, the Rajput et al. 61 study was underpowered to detect Purkinje cell loss, and the Shill et al. 62 study is problematic for reasons of case definition. Based on these negative studies, some authors consider ET may not be a neurodegenerative disease, and point to an abnormal neuronal oscillation as the fundamental abnormality in this disorder. 64, 65 The controversial results of the various neuropathologic studies in ET are difficult to explain and may be related to three possibilities: 1) patient selection biases; 2) different methodologies and counting methods; and 3) differences in field sizes and lack of standardization across studies, restricting microscopy to linear segments. 66 These biases have to be controlled in further standardized studies. Moreover, all genetic studies involving several nucleotide GABA polymorphisms and GABA A receptor and GABA transporter genes have been negative. [29] [30] [31] [32] Also of concern is the therapeutic failure of several GABAergic drugs in controlled studies. These include progabide, gabapentin, topiramate, tiagabine, and pregabaline. 37, 38, 42, 47, 49, 51, 52 Furthermore, efficacy of GABAergic drugs with antitremoric properties is relatively scarce, with maximum improvements of about 30-60%. 2 However, simply enhancing GABA neurotransmission may be too gross a solution to the problem. Loss of GABA in ET may be a marker of the problem (Purkinje cell loss) but the problem produced by Purkinje cell loss may not simply be fixed by enhancing GABA transmission.
Final remarks
To sum up and conclude, we can state that the GABA hypothesis remains the most robust pathophysiological theory of ET to date. There is light in all the steps of the GABA hypothesis. However, the evident shadows and controversies cannot be overlooked. We clearly need to perform more studies to confirm the neurodegenerative nature of the disease and more studies about the decrease in GABA activity in the cerebellum, and we need to test more therapies that enhance GABA transmission specifically focused in the cerebellum area.
